EchoGo® Heart Failure vs Study Watch
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo® Heart Failure, is an AI platform designed for rapid diagnosis of HFpEF by analyzing routine echocardiograms, providing clinical decision support. In contrast, Tool B, Verily Study Watch, is a wearable device focused on continuous physiological monitoring and data collection for clinical research. While both leverage AI in cardiology and are FDA-cleared, they address different aspects of cardiac care through distinct data sources and primary use cases.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Heart Failure is an AI platform designed as a diagnostic aid to detect Heart Failure with preserved Ejection Fraction (HFpEF) from routine echocardiograms, providing insights to support clinical decisions within 20 minutes. In contrast, Verily Study Watch is a prescription-only, sensor-based wearable device primarily for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis.
EchoGo Heart Failure analyzes a single apical 4-chamber echocardiographic video clip using deep learning AI to detect HFpEF. Study Watch collects continuous physiological data such as ECG, heart rate, electrodermal activity, and inertial movements via its wearable sensors, which is then uploaded and processed in Verily's cloud platform using algorithms and machine learning.
EchoGo Heart Failure offers seamless integration with existing workflows and IT stacks, delivering automated structured reports via DICOM to PACS within 20 minutes. Study Watch uploads collected data from the device to Verily's cloud platform for processing, primarily for research data management.
EchoGo Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF detection. It has also shown to improve classification of previously non-diagnostic cases and identify high-risk patients. Study Watch provides continuous physiological monitoring and features like an on-demand single-channel ECG and irregular pulse monitor, and has been used in studies to associate walking behavior with heart failure risk, but specific diagnostic performance metrics for conditions are not detailed for its primary research use.
EchoGo Heart Failure is designed as a diagnostic aid for routine clinical diagnosis and management of HFpEF, targeting solo to large health systems. Study Watch is primarily intended for non-invasive, continuous physiological monitoring within clinical research settings and partnerships.